Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus
Diabetes Technology & Therapeutics · 2023
DOI: 10.1089/dia.2023.0234 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Diabetes Technology & Therapeutics, 2023. Verfasst von Yu Pei und 16 weiteren Autor:innen. Beteiligte Einrichtung: Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 1, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
While evidence supports glycemic control benefits for individuals with type 1 diabetes mellitus (T1DM) using hybrid closed-loop (HCL) systems, HCL automated insulin delivery therapy in China has not been assessed. This study evaluated safety events and effectiveness during HCL system use by Chinese adolescents and adults with T1DM.
Methods
Sixty-two participants (n = 12 adolescents with a mean ± standard deviation [SD] of 15.5 ± 1.1 years and n = 50 adults [mean ± SD of 37.6 ± 11.1 years]) with T1DM and baseline A1C of 7.1% ± 1.0% underwent a run-in period (∼2 weeks) using open-loop Manual Mode (sensor-augmented pump) insulin delivery with the MiniMed™ 770G system with the Guardian™ Sensor (3) glucose sensor, followed by a study period (4 weeks) with HCL Auto Mode enabled. Analyses compared continuous glucose monitoring data and insulin delivered during the run-in versus study period (Wilcoxon signed-rank test or t-test). Safety events included rates of severe hypoglycemia and diabetic ketoacidosis (DKA).
Results
Compared to baseline run-in, overall Auto Mode use increased time in range (TIR, 70-180 mg/dL) from 75.3% to 80.9% (P 180 mg/dL) that reduced from 31.6% to 20.8%. Auto Mode use also increased the percentage achieving combined recommendations for time at sensor glucose ranges (i.e., TIR of >70%, TBR of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chinese PLA General Hospital, Beijing, China.
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Nanjing Drum Tower Hospital, Nanjing, China.
- Shanghai General Hospital, Shanghai, China.
- Medtronic, Beijing, China.
- Medtronic, Shanghai, China.
ORCID-Profile: Yan Bi, Yanbing Li, Yuri Treminio, Robert A Vigersky
Zitieren
APA
Pei, Y., Ke, W., Lu, J., Lin, Y., Zhang, Z., Peng, Y., Bi, Y., Li, Y., Hou, J., Zhang, X., Chen, X., Treminio, Y., Lee, S. W., Shin, J., Rhinehart, A. S., Vigersky, R. A., & Mu, Y. (2023). Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0234
Vancouver
Pei Y, Ke W, Lu J, Lin Y, Zhang Z, Peng Y, et al. Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus. Diabetes Technology & Therapeutics. 2023. doi:10.1089/dia.2023.0234
BibTeX
@article{Pei2023,
author = {Pei, Yu and Ke, Weijian and Lu, Jing and Lin, Yi and Zhang, Zhijian and Peng, Yongde and Bi, Yan and Li, Yanbing and Hou, Jue and Zhang, Xiaolu and Chen, Xiaoxiao and Treminio, Yuri and Lee, Scott W and Shin, John and Rhinehart, Andrew S and Vigersky, Robert A and Mu, Yiming},
title = {Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus},
journal = {Diabetes Technology & Therapeutics},
year = {2023},
doi = {10.1089/dia.2023.0234}
}
EUVIMED